Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol. 2013 Jun 11. [Epub ahead of print]
Centenera MM, Fitzpatrick AK, Tilley WD, Butler LM.Hsp90: still a viable target in prostate cancer. Biochim Biophys Acta. 2013 Apr;1835(2):211-8. Review.
Chiam K, Ryan NK, Ricciardelli C, Day TK, Buchanan G, Ochnik AM, Murti K, Selth LA; Australian Prostate Cancer BioResource, Butler LM, Tilley WD, Bianco-Miotto T. Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate. 2013 Jan;73(2):182-93.
Gates MA, Mekary RA, Chiu GR, Ding EL, Wittert GA, Araujo AB. Sex steroid hormone levels and body composition in men. J Clin Endocrinol Metab. 2013 Jun;98(6):2442-50.
Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD, Butler LM. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget. 2013 May;4(5):691-704.
Grant J, Martin SA, Taylor AW, Wilson DH, Araujo A, Adams RJ, Jenkins A, Milne RW, Hugo GJ, Atlantis E, Wittert GA. Cohort Profile: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) Study. Int J Epidemiol. 2013 Jun 19. [Epub ahead of print]
Lawrence MD, Blyth BJ, Ormsby RJ, Tilley WD, Sykes PJ. False-positive TUNEL staining observed in SV40 based transgenic murine prostate cancer models. Transgenic Res. 2013 Feb 20. [Epub ahead of print]
Martin S, Lange K, Haren MT, Taylor AW, Wittert G; Members of the Florey Adelaide Male Ageing Study. Risk factors for progression and improvement of lower urinary tract symptoms (LUTS) in a prospective cohort of men. J Urol. 2013 Jun 11. [Epub ahead of print]
Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012 Dec;2(12):1134-49.
Selth LA, Townley SL, Gillis JL, Tilley WD, Butler LM. Identification of Prostate Cancer-Associated MicroRNAs in Circulation Using a Mouse Model of Disease. Methods Mol Biol. 2013;1024:235-46.
Shi Z, Arauio AB, Martin S, O’Loughlin P, Wittert GA. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab. 2013 Jun 17. [Epub ahead of print]
Sia DI, Martin S, Wittert G, Casson RJ Age-related change in contrast sensitivity among Australian male adults: Florey Adult Male Ageing Study. . Acta Ophthalmol. 2013 Jun;91(4):312-7.
Trotta AP, Need EF, Selth LA, Chopra S, Pinnock CB, Leach DA, Coetzee GA, Butler LM, Tilley WD, Buchanan G. Knockdown of the co-chaperone SGTA results in the suppression of androgen and PI3K/AKT signaling and inhibition of prostate cancer cell proliferation. Int J Cancer. 2013 Jun 6.[Epub ahead of print]